

Date : 30th October, 2018.

To
BSE Ltd.
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001.

Sub.: Outcome of Board Meeting held today, i.e. 30th October, 2018 – Unaudited Results for the Quarter ended 30th September, 2018.

Reg.: Regulation 30(2) of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015.

Dear Sir,

Kindly note that the Audit Committee have reviewed and the Board of directors of the Company have approved the unaudited financial results for the quarter ended on 30th September, 2018 during their respective meetings held today, i.e. on 30th October, 2018.


The unaudited financial results for the quarter from 1st July, 2018 to 30th September, 2018 duly signed in the format specified under clause 30(4) of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, is enclosed.

Also enclosed alongwith is the limited audit review report of the auditors of the Company, on the unaudited financial results for the quarter ended on 30th September, 2018.

Kindly take on record the above and acknowledge.

Thanking you,

Yours faithfully,
For Jenburkt Pharmaceuticals Ltd.,



(ASHISH SHAH)
Company Secretary.

Encl.: As Stated Above.

Statement of Unaudited Standalone Financial Results for the Quarter and Half Year Ended on 30/09/2018

Rs. In Lacs other than EPS

Sr. No.	Particulars	Quarter Ended			Year to Date		Previous Year Ended
		30/09/2018	30/06/2018	30/09/2017	30/09/2018	30/09/2017	31/03/2018
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Revenue from Operations	3198.44	2325.82	3674.76	5524.26	5374.16	11467.42
2	Other Income	90.48	90.53	94.26	181.01	205.27	339.40
3	Total income	3288.92	2416.35	3769.02	5705.27	5579.43	11806.82
4	Expenses						
	(a) Cost of Materials Consumed	225.53	248.96	202.66	474.49	412.33	986.21
	(b) Purchase of Stock-in-trade	688.03	568.74	368.25	1256.77	933.84	2064.62
	(c) Changes in inventories of Finished Goods, Stock-in-trade and WIP	77.90	-108.18	417.55	-30.28	382.30	348.29
	(d) Employee benefit expenses	725.58	778.50	704.28	1504.08	1389.94	2769.18
	(e) Finance Costs	9.28	8.99	8.65	18.27	17.47	41.21
	(f) Depreciation and Amortisation Expense	33.21	31.62	38.09	64.83	74.18	150.02
	(g) other expenses	773.12	577.37	742.28	1350.49	1373.38	2920.40
	Total Expenses	2532.65	2106.00	2481.76	4638.65	4583.44	9279.93
5	Profit before exceptional items & Tax	756.27	310.35	1287.26	1066.62	995.99	2526.89
6	Exceptional Items	0.00	0.00	0.00	0.00	0.00	0.00
7	Profit before tax	756.27	310.35	1287.26	1066.62	995.99	2526.89
8	Tax Expense						
	(i) Current Tax	195.00	105.00	300.00	300.00	300.00	830.00
	(ii) Income Tax for previous years	0.00	-32.80	0.00	-32.80	0.00	14.24
	(ii) Deferred Tax	-13.11	-31.56	-10.04	-44.67	-13.37	-38.57
9	Profit after tax for the period	574.38	269.71	997.30	844.09	709.36	1721.22
10	Other Comprehensive Income						
	(i) Items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	-97.99
	(ii) Income Tax relating to Items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00
	(iii) Items that will be reclassified to profit or loss	-7.67	7.53	20.71	-0.14	20.71	27.60
	(iv) Income Tax relating to Items that will be reclassified to profit or loss	1.43	-12.11	0.00	-10.68	0.00	-0.03
11	Total Comprehensive Income for the period	568.14	265.13	1018.01	833.27	730.07	1650.80
12	Paid up Equity Share Capital (F.V. Rs.10/- each)	458.94	458.94	464.93	458.94	464.93	458.94
13	Earnings Per Share (in Rs.) (F.V. Rs.10/-) Basic and Diluted	12.52	5.88	21.45	18.39	15.26	37.50

Notes:

1

The Company has adopted Indian Accounting Standards (IND AS) prescribed under section 133 of the Companies Act 2013, read with relevant rules issued thereunder from 1st April, 2017 and accordingly, these standalone unaudited financial results (including figures for the previous quarters and year ended 31st March, 2018) have been prepared in accordance with the recognition and measurement principles laid down in Ind AS.

2 The above statement of unaudited standalone financial results were reviewed by the Audit Committee and approved by the Board of Directors at their respective meeting held on 30th October, 2018.

Science hai toh Hope hai Hope hai toh Health hai Health hai toh Happiness hai

- 3 The EPS calculated above is based on the paidup equity share capital of the Company, for the relevant quarter/year.
- 4 The Company is dealing exclusively in Pharmaceuticals business segment, hence segment wise reporting is not applicable.
- 5 The figures of the previous year/period have been regrouped/recast/rearranged to render them comparable with figures of the current period.


Place : Mumbai
Date : 30th October, 2018

By order of the Board
For Jenburkt Pharmaceuticals Ltd.


(ASHISH U BHUTA)
CHAIRMAN AND MANAGING DIRECTOR



 Science hai toh Hope hai  Hope hai toh Health hai  Health hai toh Happiness hai 

Standalone Statement of Assets and Liabilities				
				(Rs.in Lacs)
Sr. No.	Particulars	AS AT 30/09/2018	AS AT 31/03/2018	
		(Unaudited)	(Audited)	
(A)	ASSETS			
(1)	Non Current Assets			
(a)	Property, Plants & Equipments	949.21	944.91	
(b)	Goodwill	0.14	0.14	
(c)	Other Intangible assets	74.07	11.78	
(d)	Financial Assets			
(i)	Investments	168.75	162.82	
(ii)	Loans	21.34	10.30	
(iii)	Others	0.00	0.00	
(e)	Other non-current assets	0.00	25.03	
(f)	Deferred Tax Assets (Net)	22.19	0.00	
(2)	Current Assets			
(a)	Inventories	806.35	680.44	
(b)	Financial Assets			
(i)	Investments	355.36	378.78	
(ii)	Trade receivables	1445.76	1253.78	
(iii)	Cash and cash equivalents	36.73	118.37	
(iv)	Bank balance other than (iii)	4437.97	3992.98	
(v)	Loans	32.16	28.85	
(vi)	Others	60.86	53.41	
(c)	Other current assets	164.68	85.56	
(d)	Current Tax Asset (Net)	21.94	0.00	
	Total Assets	8597.51	7747.14	
(B)	EQUITY AND LIABILITIES			
	Equity			
(a)	Equity Share capital	458.94	458.94	
(b)	Other Equity - Reserves & Surplus	6168.38	5667.09	
	Liabilities			
(1)	Non Current Liabilities			
(a)	Financial Liabilities - Borrowings	0.00	23.59	
(b)	Deferred tax liabilities (Net)	0.00	11.79	
(c)	Other non-current liabilities	293.09	278.79	
(2)	Current Liabilities			
(a)	Financial Liabilities			
(i)	Borrowings	329.79	0.53	
(ii)	Trade payables	756.63	412.21	
(iii)	Other financial liabilities	443.59	677.77	
(b)	Other current liabilities	128.47	189.18	
(c)	Provisions	18.62	18.62	
(d)	Current tax liabilities (Net)	0.00	8.62	
	Total Equity and Liabilities	8597.51	7747.14	
		By order of the Board		
		For Jenburkt Pharmaceuticals Ltd.		
				
		(ASHISH U BHUTA)		
		CHAIRMAN AND MANAGING DIRECTOR		
	Place : Mumbai			
	Date : 30 th October, 2018			

D.R.MEHTA & ASSOCIATES

(CHARTERED ACCOUNTANTS)

H-2, EVEREST BUILDING, 9TH FLOOR, TARDEO CIRCLE, MUMBAI –
400034. TEL: 23513758 / 23520330, 9322508373

Email ID: info@drmehta.in, vikram@drmehta.in, ashok@drmehta.in

Review Report to
The Board of Directors

Jenburkt Pharmaceuticals Ltd.

We have reviewed the accompanying statement of unaudited financial results of Jenburkt Pharmaceuticals Ltd. for the quarter ended 30th September 2018. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, *Engagements to Review Financial Statements* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For D R Mehta & Associates
Chartered Accountants
(FRN. 106207W)



Signature
Ashok Mehta
Partner
(M. No.: 101746)



Place: Mumbai
Date: 30th October, 2018